Detroit families should not have to wait half a school year — or spend thousands of dollars — to understand what support their children need.

A number of healthcare organizations have recently closed medical departments or ended services at facilities to shore up finances, focus on more ...

ELZONRIS leverages first-mover status, global approvals, strong clinical adoption and expansion into CD123-positive cancers, backed by pricing and competitive analysis.Dublin, Oct. 09, 2026 (GLOBE ...

Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEAD study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor ...

A European consortium has issued a new evidence-based recommendation for managing peripheral venous access devices in ...

TRIAD, the autism institute at the Vanderbilt Kennedy Center (VKC), pioneered using telehealth to assess for autism in young ...

Hanover, N.H.-based Argus Cognitive’s Neurora, a software tool that analyzes behavioral data to assist clinicians in ...

The AAP’s newest guidance on diagnosing and treating UTIs in children aged 8 days to 5 years recommends shorter antibiotic ...

Cholestasis nutrition products market to grow from USD 107.6 Mn in 2026 to USD 223.8 Mn by 2036 at a 7.6% CAGR. Get segment, ...

Quoin Pharmaceuticals publishes a paper on QRX003 for Netherton Syndrome, detailing positive pediatric case report outcomes. Quoin Pharmaceuticals has announced the acceptance of a peer-reviewed paper ...

Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton SyndromeCase Report Details Professor Alan ...

Quoin Pharmaceuticals Ltd. announced that a manuscript titled ?An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case ...